Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shugan Jieyu Capsule for Sleep and Mood Disorders in Post-COVID-19 Convalescence
ChiCTR2100043108Phase 4Recruiting
- Sponsor
- Hubei Provincial Traditional Chinese Medical Hospital
- Start
- Jul 2020
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in sleep disorder, major depressive disorder (MDD), anxiety disorder and 3 more comparing Shugan Jieyu Capsule with Placebo (Shugan Jieyu Capsule Simulator) (2 arms). Primary endpoint: Hamilton Depression Scale. Started Jul 2020; status: recruiting.
02
Drugs
Shugan Jieyu
03
Conditions
sleep disordermajor depressive disorder (MDD)anxiety disordersomatic symptom disorder (SSD)asthenia
Beyond the preview
Go deeper on ChiCTR2100043108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043108.